[Salsolinol, 3-O-methyl-dopa and homovanillic acid in the cerebrospinal fluid of Parkinson patients].
Salsolinol is one of the dopamine-derived tetrahydroisoquinolines, supposed to be a potent dopaminergic neurotoxin, similar to MPTP. Its systemic administration induced parkinsonism in monkeys. The aim of the study was to compare the concentration of salsolinol and the metabolite of L-dopa, 3-O-MD, and the metabolite of dopamine, HVA, in the cerebrospinal fluid of patients with different degrees of parkinsonism, treated or nontreated with l-dopa. Lumbar CSF was obtained from 26 patients with Parkinson's disease (15 early and 11 advanced parkinsonism) and from six healthy controls. The presence of salsolinol, HVA and 3-O-MD was assayed with a sensitive HPLC method employing C18 (Hypersil BDS) column. The analysis of the results demonstrated that the concentration of salsolinol was related to the degree of parkinsonism but not affected by l-dopa treatment. In contrast, HVA and 3-O-MD were significantly elevated in patients receiving l-dopa but did not correlate with the severity of parkinsonism. The results suggest that salsolinol in the cerebrospinal fluid does not originate from exogenous l-dopa and its elevation in cerebrospinal fluid may be an indicator of the advancement of parkinsonism.
Krygowska-Wajs
A
A
Kliniki Neurologii Coll. Med. UJ, Krakowie.
Szczudlik
A
A
Antkiewicz-Michaluk
L
L
Romańska
I
I
Vetulani
J
J
D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid* / Q000627:therapeutic use; D006801:Humans; D007546:Isoquinolines / Q000134:cerebrospinal fluid*; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D012720:Severity of Illness Index; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000134:cerebrospinal fluid
D000978:Antiparkinson Agents; D007546:Isoquinolines; D014443:Tyrosine; D007980:Levodopa; C036617:salsolinol; C008404:3-methoxytyrosine; D006719:Homovanillic Acid
Salsolinol oraz 3-0-metyldopa i kwas homowanilinowy w płynie mózgowo-rdzeniowym u osób z choroba parkinsona.